Work

Methodological validation of Miro1 retention as a candidate Parkinson’s disease biomarker

Year: 2025

Type: article

Abstract: Mitochondrial markers help stratify Parkinson's disease (PD) patients. We use high-throughput blotting to quantify Miro1, Mfn2, and VDAC levels in fibroblasts, blood cells, and iPSC-derived neurons. Miro1 is specifically retained in PD cells but degraded in healthy ones after mitochondrial depolarization. We correlate Miro1 retention scores with pathogenic mutations, genetic background, age, and clinical data. This scalable assay and quantifiable score for mitochondrial-PD support biomarker development and pharmacological screening.

Source: npj Parkinson s Disease

DOI: 10.1038/s41531-025-01115-8

Authors: Layla Drwesh, Giuseppe Arena, Daniel J. Merk, Daniele Ferrante, Vyron Gorgogietas, Thomas Gasser, Anne Grünewald, Patrick May, Kathrin Brockmann, Rejko Krüger, Richard Wüst, Christian Johannes Gloeckner, Julia C. Fitzgerald

Institutions: Hertie Institute for Clinical Brain Research, University of Tübingen, University of Luxembourg, Luxembourg Centre for Systems Biomedicine, German Center for Neurodegenerative Diseases, Centre Hospitalier de Luxembourg, Luxembourg Institute of Health

Language: English

Topic: Parkinson's Disease Mechanisms and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,890

Funders: Michael J. Fox Foundation for Parkinson's Research, Eberhard Karls Universität Tübingen, National Institute of Neurological Disorders and Stroke

Award: G5239954132

OpenAlex ID: W4414201973

FWCI: 2.731

Cites: 29

Cited by: 5

Related to: